Back to top
more

Globus Medical (GMED)

(Delayed Data from NYSE)

$56.22 USD

56.22
1,419,026

-1.62 (-2.80%)

Updated Sep 17, 2025 04:00 PM ET

After-Market: $56.22 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (86 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Globus Medical (GMED) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 30.91% and 3.41%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wall Street's Insights Into Key Metrics Ahead of Globus Medical (GMED) Q1 Earnings

by Zacks Equity Research

Evaluate the expected performance of Globus Medical (GMED) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Equity Research

GMED vs. PEN: Which Stock Is the Better Value Option?

by Zacks Equity Research

GMED vs. PEN: Which Stock Is the Better Value Option?

Zacks Equity Research

Why Globus Medical (GMED) is a Top Momentum Stock for the Long-Term

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Globus Medical (GMED) Gains From New Launches Amid Macro Issues

by Zacks Equity Research

Globus Medical (GMED) witnesses notable gains across its product portfolio in expandables, biologics, MIS screws, 3D printed implants and cervical offerings.

Zacks Equity Research

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Globus Medical (GMED) Down 5.8% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Equity Research

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.

Zacks Equity Research

Here's Why Globus Medical (GMED) is a Strong Value Stock

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks Equity Research

Here's Why Globus Medical (GMED) is a Strong Momentum Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings Surpass, Margins Down

by Zacks Equity Research

Globus Medical's (GMED) fourth-quarter 2023 performance benefits from innovative launches across its product groups.

Zacks Equity Research

Compared to Estimates, Globus Medical (GMED) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

The headline numbers for Globus Medical (GMED) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Globus Medical (GMED) delivered earnings and revenue surprises of 1.69% and 0.74%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Higher Visits to Soften Cost Blow for Teladoc (TDOC) Q4 Earnings

by Zacks Equity Research

Teladoc's (TDOC) fourth-quarter results are likely to reflect growth in BetterHelp's profit levels.

Zacks Equity Research

Can Low Patient Days Affect Community Health (CYH) Q4 Earnings?

by Zacks Equity Research

Community Health's (CYH) fourth-quarter results are likely to reflect lower adjusted admissions, declining beds in services and occupancy rate.

Zacks Equity Research

Will Nevro (NVRO) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Globus Medical (GMED) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Zacks Equity Research

The Zacks Analyst Blog Highlights Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics

by Zacks Equity Research

Globus Medical, Glaukos, PROCEPT, Edwards Lifesciences and Quest Diagnostics are included in this Analyst Blog.

Zacks Equity Research

Globus Medical (GMED) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

3 Medtech Stocks Likely to Top Estimates This Earnings Season

by Urmimala Biswas

Here are three stocks, GMED, GKOS and PRCT, which are expected to beat earnings estimates in the ongoing reporting cycle.

Zacks Equity Research

Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?

by Zacks Equity Research

Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.

Zacks Equity Research

Encompass Health (EHC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.

Zacks Equity Research

Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?

by Zacks Equity Research

Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.